CTi Biopharma CorpCTIC:NAQ

0.019 / 5.94%
84.93 %
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 12 2016 21:00 GMT.

Consensus recommendation

As of Feb 10, 2016, the consensus forecast amongst 4 polled investment analysts covering CTI BioPharma Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 10, 2016. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
No opinion0

Research Reports

S&P Capital IQ Quantitative Report
Ford Investor Services, Inc.

Share price forecast

The 4 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 2.13, with a high estimate of 5.00 and a low estimate of 0.00. The median estimate represents a 526.66% increase from the last price of 0.3391. View Full Financials


Dividend information is not available for CTi Biopharma Corp. View Full Financials

Earnings history & estimates

On Nov 05, 2015, CTI BioPharma Corp reported 3rd quarter 2015 losses of -0.18 per share. This result under-performed the -0.140 loss expectation of the 3 analysts following the company but under-performed last year's 3rd quarter results by -0.21. View Full Interim Financials

Average growth rate-9.26 %

CTI BioPharma Corp reported annual 2014 losses of -0.49 per share on Mar 12, 2015. View Full Annual Financials

Average growth rate+38.73 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement


CTI BioPharma Corp. had 3rd quarter 2015 revenues of 964.00k. This missed the 14.74m consensus estimate of the 3 analysts following the company. This was 97.56 % below the prior year's 3rd quarter results. View Full Interim Financials

Average growth rate-52.93 %

CTI BioPharma Corp. had revenues for the full year 2014 of 60.08m. This was 2,496.24% above the prior year's results. View Full Annual Financials

Average growth rate+798.75 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.